From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Esomeprazole Therapy for Asthma: Marginal Benefit

Asthma patients received little benefit from potent acid suppression.

An association between gastroesophageal reflux disease (GERD) and asthma is acknowledged widely, but the effect of GERD therapy on asthma control has been inconsistent in previous studies. Some research has suggested a particular association between GERD and nocturnal asthma symptoms.

This industry-sponsored trial included 3 subgroups of adults with stable asthma: One subgroup had nocturnal asthma symptoms and no GERD, one had GERD and no nocturnal asthma symptoms, and one had both GERD and nocturnal asthma symptoms. All 700 patients were randomized to receive either esomeprazole (Nexium; 40 mg) or placebo twice daily. Nearly all patients used inhaled corticosteroids.

The primary outcome was change in mean morning peak expiratory flow (PEF). Compared with placebo, esomeprazole did not significantly improve morning PEF at 16 weeks in any of the subgroups, although the difference between placebo and esomeprazole in the entire study population approached significance (P=0.06). Esomeprazole was associated with a small but statistically significant improvement in one secondary outcome — evening PEF — in the subgroup with both GERD and nocturnal symptoms (mean change, 309 L/min to 335 L/min with esomeprazole and 315 L/min to 329 L/min with placebo; P=0.02). However, other secondary outcomes (e.g., use of rescue inhalers, quality-of-life scores) did not improve with esomeprazole.

Comment: In this study, potent acid-suppressive therapy resulted in only marginal benefit among asthma patients — even those with both GERD and nocturnal asthma symptoms. The authors acknowledge a need for additional research to identify patients with asthma who clearly will benefit from acid suppression.

— Allan S. Brett, MD

Published in Journal Watch General Medicine June 6, 2006

Citation(s):

Kiljander TO et al. Effects of esomeprazole 40 mg twice daily on asthma: A randomized placebo-controlled trial. Am J Respir Crit Care Med 2006 May 15; 173:1091-7.

Reader Remarks:

Read all Reader Remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

(more...)

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2006. Massachusetts Medical Society. All rights reserved.